Elevated serum creatine kinase levels due to osimertinib: A case report and review of the literature. (March 2022)

• Record Type: Journal Article
• Authors: Sugimoto, Hiroshi; Matsumoto, Satoshi; Tsuji, Yukio; Sugimoto, Keisuke
• Is Part Of: Journal of oncology pharmacy practice. Volume 28:Number 2(2022)
• Page Start: 489
• Page End: 494
• Publication Date: 2022-03
• Subjects: Lung cancer -- epidermal growth factor receptor-tyrosine kinase inhibitor -- osimertinib -- creatine kinase -- myotoxicity; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/10781552211042271
• Languages: English
• ISSNs: 1078-1552

Abstract

Introduction: Osimertinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor. Elevated serum creatine kinase level is an uncommon adverse event associated with osimertinib treatment for lung cancer. Case Report: We report a previously healthy 56-year-old woman who developed elevated serum creatine kinase levels during osimertinib monotherapy for epidermal growth factor receptor mutation-positive lung adenocarcinoma. Management & Outcome: During treatment, she experienced leg cramps and her serum creatine kinase levels increased, peaking at 989 U/l. Further investigation revealed no evidence of cardiotoxicity or myositis; thus, osimertinib-induced myopathy was assumed to be the cause of her elevated serum creatine kinase levels. We successfully managed both lung cancer and osimertinib-induced myopathy using 1-week pauses of osimertinib therapy without dose reduction. Discussion: Short-term suspension of osimertinib without dose reduction may be a reasonable option for osimertinib-induced myopathy.